Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cardiovascular Toxicology
Published in: Cardiovascular Toxicology 1/2019

01-02-2019

Beneficial Effect of Silymarin in Pressure Overload Induced Experimental Cardiac Hypertrophy

Authors: Basant Sharma, Udit Chaube, Bhoomika M. Patel

Published in: Cardiovascular Toxicology | Issue 1/2019

Login to get access

Abstract

The present investigation was undertaken to study the effect of silymarin on cardiac hypertrophy induced by partial abdominal aortic constriction (PAAC) in Wistar rats. Silymarin was administered for 9 weeks at the end of which we evaluated hypertrophic, hemodynamic, non-specific cardiac markers, oxidative stress parameters, and determined mitochondrial DNA concentration. Hypertrophic control animals exhibited cardiac hypertrophy, altered hemodynamics, oxidative stress, and decreased mitochondrial DNA (mtDNA) concentration. Treatment with silymarin prevented cardiac hypertrophy, improved hemodynamic functions, prevented oxidative stress and increased mitochondrial DNA concentration. Docking studies revealed that silymarin produces maximum docking score with mitogen-activated protein kinases (MAPK) p38 as compared to other relevant proteins docked. Moreover, PAAC-control rats exhibited significantly increased expression of MAPK p38β mRNA levels which were significantly decreased by the treatment of silymarin. Our data suggest that silymarin produces beneficial effects on cardiac hypertrophy which are likely to be mediated through inhibition of MAPK p38β.
Literature
1.
Anan, R., Nakagawa, M., Miyata, M., Higuchi, I., Nakao, S., Suehara, M., et al. (1995). Cardiac involvement in mitochondrial diseases. A study on 17 patients with documented mitochondrial DNA defects. Circulation, 91(4), 955–961.CrossRef
2.
Andrews, C., Ho, P., Dillmann, W., Glembotski, C., & McDonoughc, P. (2003). The MKK6–p38 MAPK pathway prolongs the cardiac contractile calcium transient, downregulates SERCA2, and activates NF-AT. Cardiovascular Research, 59, 46–56.CrossRef
3.
Anton, R., Bauer, S. M., Keck, P., & Laufer, P. (2014). A p38 Substrate-Specific MK2-EGFP translocation assay for identification and validation of new p38 inhibitors in living cells: A comprising alternative for acquisition of cellular p38 inhibition. PLoS ONE, 9, e95641.CrossRef
4.
Barja, G., & Herrero, A. (2000). Oxidative damage to mitochondrial DNA is inversely related to maximum life span in the heat and brain of mammals. The FASEB Journal, 14, 312–318.CrossRef
5.
Bernardo, B. C., Weeks, K. L., Pretorius, L., & McMullen Jr. (2010). Molecular distinction between physiological and pathological cardiac hypertrophy: Experimental findings and therapeutic strategies. Pharmacology & Therapeutics, 128, 191–227.CrossRef
6.
Borah, A., Paul, R., Choudhury, S., Choudhury, A., Bhuyan, B., Talukdar, D., A., et al (2013). Neuroprotective potential of silymarin against CNS disorders: Insight into the pathways and molecular mechanisms of action. CNS Neuroscience Therapeutics, 19, 847–853.CrossRef
7.
Buckley, D. I., Fu, R., Freeman, M., Rogers, K., & Helfand, M. (2009). C-reactive protein as a risk factor for coronary heart disease: A systematic review and meta-analyses for the U.S. Preventive Services Task Force. Annals of Internal Medicine, 151, 483–495.CrossRef
8.
Bugger, H., & Abel, E. D. (2010). Mitochondria in the diabetic heart. Cardiovascular Research, 88, 229–240.CrossRef
9.
Chen, P. N., Hsieh, Y. S., Chiou, H. L., & Chu, S. C. (2005). Silibinin inhibits cell invasion through inactivation of both PI3K-Akt and MAPK signaling pathways. Chemico-Biological Interactions, 156(2–3), 141–150.CrossRef
10.
Dai, D. F., Johnson, S. C., Villarin, J. J., Chin, M. T., Nieves-Cintron, M., Chen, T., et al. (2011). Mitochondrial oxidative stress mediates angiotensin II-induced cardiac hypertrophy and Galphaq overexpression-induced heart failure. Circulation Research, 108, 837–846.CrossRef
11.
Dhalla, N. S., Temsah, R. M., & Netticadan, T. (2000). Role of oxidative stress in cardiovascular diseases. Journal of Hypertension, 18, 655–673.CrossRef
12.
Dickhout, J. G., Carlisle, R. E., & Austin, R. C. (2011). Interrelationship between cardiac hypertrophy, heart failure, and chronic kidney disease: Endoplasmic reticulum stress as a mediator of pathogenesis. Circulation Research, 108(5), 629–642.CrossRef
13.
Elkamhawy, A., Lee, J., Park, B. G., Park, I., Pae, A. N., & Roh, E. J. (2014). Novel quinazoline-urea analogues as modulators for Aβ-induced mitochondrial dysfunction: Design, synthesis, and molecular docking study. European Journal of Medicinal Chemistry, 84, 466–475.CrossRef
14.
Frey, N., & Olson, E. N. (2003). Cardiac hypertrophy: The good, the bad, and the ugly. Annual Review of Physiology, 65, 45–79.CrossRef
15.
Gabrielová, E., Zholobenko, A. V., Bartošíková, L., Nečas, J., & Modriansky, M. (2015). Silymarin constituent 2,3-dehydrosilybin triggers reserpine-sensitive positive inotropic effect in perfused rat heart. PLoS ONE, 10(9), e0139208.CrossRef
16.
Gharagozloo, M., Jafari, S., Esmaeil, N., Javid, E. N., Bagherpour, B., & Rezaei, A. (2013). Immunosuppressive effect of silymarin on mitogen-activated protein kinase signalling pathway: The impact on T cell proliferation and cytokine production. Basic & Clinical Pharmacology & Toxicology, 113, 209–214.CrossRef
17.
Goyal, B. R., & Mehta, A. A. (2012). Beneficial role of spironolactone, telmisartan and their combination on isoproterenol induced cardiac hypertrophy. Acta Cardiologica, 67, 203–211.CrossRef
18.
Goyal, B. R., & Mehta, A. A. (2013). Diabetic cardiomyopathy: Pathophysiological mechanisms and cardiac dysfunction. Human & Experimental Toxicology, 32, 571–590.CrossRef
19.
Goyal, B. R., Mesariya, P., Goyal, R. K., & Mehta, A. A. (2008). Effect of telmisartan on cardiovascular complications associated with streptozotocin diabetic rats. Molecular and Cellular Biochemistry, 314, 123–131.CrossRef
20.
Goyal, B. R., Parmar, K., Goyal, R. K., & Mehta, A. A. (2011). Beneficial role of telmisartan on cardiovascular complications associated with STZ-induced type-2 diabetic rats. Pharmacological Reports, 63, 956–966.CrossRef
21.
Goyal, B. R., Patel, M. M., & Bhadada, S. V. (2011). Comparative evaluation of spironolactone, atenolol, metoprolol, ramipril and perindopril on diabetes induced cardiovascular complications in type 1 diabetes in rats. International Journal of Diabetes and Metabolism, 19, 11–18.
22.
Goyal, B. R., Solanki, N., Goyal, R. K., & Mehta, A. A. (2009). Investigation into the cardiac effects of spironolactone in the experimental model of type 1 diabetes. Journal of Cardiovascular Pharmacology, 54, 502–509.CrossRef
23.
Hakan, A. Y., Arsava, M., & Okay, S. (2002). Creatine kinase-MB elevation after stroke is not cardiac in origin. Stroke 33, 286–290.
24.
Horton, J. W., Tan, J., White, J., & Maass, D. (2007). Burn injury decreases myocardial Na- K-ATPase activity: Role of PKC inhibition. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 293, R1684–R1692.CrossRef
25.
Huang, Q., Wu, L. J., Tashiro, S., Onodera, S., Li, L. H., & Ikejima, T. (2005). Silymarin augments human cervical cancer HeLa cell apoptosis via P38/JNK MAPK pathways in serum-free medium. Journal of Asian Natural Products Research, 7(5), 701–709.CrossRef
26.
Karamanlidis, G., Bautista-Hernandez, V., Fynn-Thompson, F., Del Nido, P., & Tian, R. (2011). Impaired mitochondrial biogenesis precedes heart failure in right ventricular hypertrophy in congenital heart disease. Circulation: Heart Failure, 4, 707–713.
27.
28.
Kumphune, S., Chattipakorn, S., & Chattipakorn, N. (2012). Role of p38 inhibition in cardiac ischemia/reperfusion injury. European Journal of Clinical Pharmacology, 68, 513–524.CrossRef
29.
Lee, J. K., & Kim, N. J. (2017). Recent advances in the inhibition of p38 MAPK as a potential strategy for the treatment of Alzheimer’s disease. Molecules, 22(8), E1287.CrossRef
30.
31.
Molkentin, J. D., & Dorn, G. W. (2001). Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annual Review of Physiology, 63, 391–426.CrossRef
32.
Patel, B. M. (2018). Sodium butyrate controls cardiac hypertrophy in experimental models of rats. Cardiovascular Toxicology, 18(1), 1–8.CrossRef
33.
Patel, B. M., Agarwal, S. S., & Bhadada, S. V. (2012). Perindopril protects against streptozotocin induced hyperglycemic myocardial damage/alterations. Human & Experimental Toxicology, 31(11), 1138–1149.CrossRef
34.
Patel, B. M., & Desai, V. J. (2014). Beneficial role of tamoxifen in experimentally induced cardiac hypertrophy. Pharmacological Reports, 66, 264–272.CrossRef
35.
Patel, B. M., & Bhadada, S. V. (2014). Type 2 diabetes induced cardiovascular complications: Comparative evaluation of spironolactone, atenolol, metoprolol, ramipril and perindopril. Clinical and Experimental Hypertension, 36, 340–347.CrossRef
36.
Patel, B. M., Kakadiya, J., Goyal, R. K., & Mehta, A. A. (2013). Effect of spironolactone on cardiovascular complications associated with type-2 diabetes in rats. Experimental and Clinical Endocrinology, 121, 441–447.CrossRef
37.
Patel, B. M., Mehta, A. A. (2013). The choice of anti-hypertensive agents in diabetic subjects. Diabetes and Vascular Disease Research, 10, 385–396.CrossRef
38.
Patel, B. M., & Mehta, A. A. (2012). Aldosterone and angiotensin: Role in diabetes and cardiovascular diseases. European Journal of Pharmacology, 697, 1–12.CrossRef
39.
Patel, B. M., Raghunathan, S., & Porwal, U. (2014). Cardioprotective effects of magnesium valproate in type 2 diabetes mellitus. European Journal of Pharmacology, 728, 128–134.CrossRef
40.
Peppers, V., Ramos, G., Manias, E., Koroboki, E., Rokas, S., & Zakopoulos, N. (2008). Correlation between myocardial enzyme serum levels and markers of inflammation with severity of coronary artery disease and Gensini score: A hospital-based prospective study in Greek patients. Clinical Interventions in Aging, 3, 699–710.CrossRef
41.
Post-White, J., Ladas, E. J., & Kelly, K. M. (2007). Advances in the use of milk thistle (Silybum marianum). Integrative Cancer Therapies, 6, 104–109.CrossRef
42.
Prockop, D. J., & Udenfriend, S. (1960). A specific method for the analysis of hydroxyproline in tissues and urine. Analytical Biochemistry, 1, 228–239.CrossRef
43.
Raghunathan, S., & Patel, B. M. (2013). Therapeutic implications of small interfering RNA in cardiovascular diseases. Fundamental and Clinical Pharmacology, 27, 1–20.CrossRef
44.
Rao, P. R., & Viswanath, R. K. (2007). Cardioprotective activity of silymarin in ischemia-reperfusion-induced myocardial infarction in albino rats. Experimental & Clinical Cardiology, 12, 179–187.
45.
Rayabarapu, N., & Patel, B. M. (2014). Beneficial role of tamoxifen in isoproterenol induced myocardial infarction. Canadian Journal of Physiology and Pharmacology, 92, 849–857.CrossRef
46.
Rosca, M. G., Tandler, B., & Hoppel, C. L. (2013). Mitochondria in cardiac hypertrophy and heart failure. Journal of Molecular and Cellular Cardiology, 55, 31–41.CrossRef
47.
Rose, B. A., Force, T., & Wang, Y. (2010). Mitogen-activated protein kinase signaling in the heart: Angels versus demons in a heart-breaking tale. Physiological Reviews, 90, 1507–1546.CrossRef
48.
Sakottova, N., Vecera, R., Urbenek, K., Vana, P., Walterova, D., & Cvak, L. (2003). Effects of polyphenolic fraction of silymarin on lipoprotein profile in rats fed cholesterol-rich diets. Pharmacological Research, 47, 17–26.CrossRef
49.
Sanz-Moreno, V., & Crespo, P. (2003). p38 mitogen-activated protein kinases: Their role in carcinogenesis. Revista de oncología, 5, 320–330.
50.
Thakare, V. N., Aswar, M. K., Kulkarni, Y. P., Patil, R. R., & Patel, B. M. (2017). Silymarin ameliorates experimentally induced depressive like behavior in rats: Involvement of hippocampal BDNF signaling, inflammatory cytokines and oxidative stress response. Physiology & Behavior, 179, 401–410.CrossRef
51.
Thakare, V. N., Dhakane, V. D., & Patel, B. M. (2016). Potential antidepressant-like activity of silymarin in the acute restraint stress in mice: Modulation of corticosterone and oxidative stress response in cerebral cortex and hippocampus. Pharmacological Reports, 68, 1020–1027.CrossRef
52.
Thakare, V. N., Patil, R. R., Oswal, R. J., Dhakane, V. D., Aswar, M. K., & Patel, B. M. (2018). Therapeutic potential of silymarin in chronic unpredictable mild stress induced depressive-like behavior in mice. Journal of Psychopharmacology, 32, 223–235.CrossRef
53.
Tsimaratos, M., Coste, T. C., Djemli-Shipkolye, A., Daniel, L., Shipkolye, F., Vague, P., & Raccah, D. (2001). Evidence of time-dependent changes in renal medullary Na,K-ATPase activity and expression in diabetic rats. Cellular Molecular Biology (Noisy-le-grand), 47, 239–245.
54.
Tuorkey, M. J., El-Desouki, N. I., & Kamel, R. A. (2015). Cytoprotective effect of Silymarin against diabetes-induced cardiomyocyte apoptosis in diabetic rats. Biomedical and Environmental Sciences, 28(1), 36–43.PubMed
55.
Wang, Y., Huang, S., Sah, V. P., Ross, J., Brown, J. H., Han, J., & Chien, K. R. (1998). Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. Journal of Biological Chemistry, 273, 2161–2168.CrossRef
56.
Wu, J. H., Hagaman, J., Kim, S., Reddick, R. L., & Maeda, N. (2002). Aortic constriction exacerbates atherosclerosis and induces cardiac dysfunction in mice lacking apolipoprotein E. Arteriosclerosis, Thrombosis, and Vascular Biology, 22(3), 469–475.CrossRef
57.
Zhang, S., Weinheimer, C., Courtois, M., Kovacs, A., Zhang, C. E., Cheng, A. M., Wang, Y., & Muslin, A. J. (2003). The role of the Grb2-p38 MAPK signaling pathway in cardiac hypertrophy and fibrosis. Journal of Clinical Investigation, 111, 833–841.CrossRef
58.
Zholobenko, A., & Modriansky, M. (2014). Silymarin and its constituents in cardiac preconditioning. Fitoterapia, 97, 122–132.CrossRef
59.
Zhou, B., Wu, L. J., Tashiro, S., Onodera, S., Uchiumi, F., & Ikejima, T. (2007). Activation of extracellular signal-regulated kinase during silibinin-protected, isoproterenol-induced apoptosis in rat cardiac myocytes is tyrosine kinase pathway-mediated and protein kinase C-dependent. Acta Pharmacologica Sinica, 28(6), 803–810.CrossRef
Metadata
Title
Beneficial Effect of Silymarin in Pressure Overload Induced Experimental Cardiac Hypertrophy
Authors
Basant Sharma
Udit Chaube
Bhoomika M. Patel
Publication date
01-02-2019
Publisher
Springer US
Published in
Cardiovascular Toxicology / Issue 1/2019
Print ISSN: 1530-7905
Electronic ISSN: 1559-0259
DOI
https://doi.org/10.1007/s12012-018-9470-2

Other articles of this Issue 1/2019

Cardiovascular Toxicology 1/2019 Go to the issue

OriginalPaper

Anti-fibrotic Actions of Roselle Extract in Rat Model of Myocardial Infarction

OriginalPaper

Long-Term IL-2 Incubation-Induced L-type Calcium Channels Activation in Rat Ventricle Cardiomyocytes

OriginalPaper

Increased Plasma Nitrite and von Willebrand Factor Indicates Early Diagnosis of Vascular Diseases in Chemotherapy Treated Cancer Patients

OriginalPaper

Predictive Role of the Cervical Sympathetic Trunk Ischemia on Lower Heart Rates in an Experimentally Induced Stenoocclusive Carotid Artery Model by Bilateral Common Carotid Artery Ligation

OriginalPaper

Refractory Arrhythmias in a Young Patient Poisoned by Imipramine

OriginalPaper

Electrocardiographic Findings in Mortalities Due to Pure Methadone Toxicity

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits